# BIOPORTO A/S

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/bioporto).

## Overview

BIOPORTO A/S is a Danish in vitro diagnostics company focused on kidney biomarker tests for clinical decision-making. Its core business is the development and commercialization of NGAL-based assays used to aid the risk assessment and diagnosis of acute kidney injury, sold under regulatory clearances and registrations in multiple markets.

## Products & services

• NGAL-based diagnostic tests for acute kidney injury
• Biomarker assays for kidney injury risk assessment
• Clinical diagnostic products sold under CE mark registrations
• FDA-cleared NGAL test offerings
• Assay development and biomarker platform R&D

- **NGAL diagnostic tests** (80%) — Commercial assays that measure NGAL to support early detection and risk assessment of acute kidney injury.
- **Other biomarker products** (10%) — Adjacent kidney biomarker products and related diagnostic offerings beyond the core NGAL line.
- **Research-use and assay development** (10%) — Development-stage biomarker work and related research-use products and services.

- NGAL-based diagnostic tests for acute kidney injury
- Biomarker assays for kidney injury risk assessment
- Clinical diagnostic products sold under CE mark registrations
- FDA-cleared NGAL test offerings
- Assay development and biomarker platform R&D

## Customers

BioPorto sells into hospitals, clinical laboratories, and healthcare providers that need earlier insight into kidney injury risk. Its products are used by clinicians managing patients where rapid AKI identification can affect treatment decisions and outcomes. The company also serves distribution and diagnostic channel partners that help commercialize regulated IVD products across geographies.

- **Hospitals and acute care providers** (primary) — Buy NGAL tests for patients at risk of acute kidney injury to support faster clinical decisions.
- **Clinical laboratories** (primary) — Use the assays in routine or specialized testing workflows where kidney biomarkers are needed.
- **Healthcare systems and physicians** (secondary) — Adopt the tests to improve patient management, diagnosis timing, and care pathways.
- **Diagnostic distributors** (secondary) — Purchase and resell regulated diagnostic products into local healthcare markets.
- **Research and development users** (secondary) — Use research-use antibodies and biomarker tools for assay development and evaluation.

- Hospitals using NGAL tests for acute kidney injury assessment
- Clinical laboratories running biomarker-based diagnostic workflows
- Physicians and care teams needing earlier AKI risk insight
- Healthcare systems seeking improved triage and patient management
- Diagnostic distributors and channel partners in regulated markets

## Geography

BioPorto is headquartered in Denmark and operates as a regulated diagnostics business with international commercial reach. Its NGAL products are marketed under CE mark registrations in several countries worldwide and include FDA-cleared offerings, indicating activity across Europe and the United States as key markets. Geography matters because regulatory approvals, reimbursement pathways, and distributor coverage shape where the tests can be sold and adopted.

- Headquartered in Denmark
- Commercial products sold in several countries worldwide
- CE mark registrations support European market access
- FDA-cleared products support U.S. commercialization
- International adoption depends on local regulatory clearance

## Strategy

BioPorto's stated direction is to focus on its core NGAL platform and the biomarker tests most closely tied to acute kidney injury care. The business strategy centers on expanding the clinical footprint of its regulated diagnostics, while using assay-development expertise to build a pipeline of kidney biomarker products. This focus matters because a narrower product strategy can strengthen commercialization, regulatory execution, and clinical relevance.

- **Grow NGAL commercialization** (short-term) — The core business depends on converting regulatory approvals into routine clinical use.
- **Broaden the biomarker pipeline** (medium-term) — Additional kidney biomarker products can reduce dependence on a single assay family.
- **Strengthen international market access** (medium-term) — Cross-border regulatory and distribution coverage is essential for scaling a diagnostics platform.

- Focus on the core NGAL kidney biomarker platform
- Expand commercial adoption of regulated AKI diagnostics
- Use assay-development expertise to build a biomarker pipeline
- Pursue markets where clinical and economic need is clear
- Maintain regulatory coverage across major healthcare markets

## Risks

BioPorto's main risks stem from regulatory dependence, adoption uncertainty, and concentration on a narrow diagnostic platform. As an in vitro diagnostics company, it also faces reimbursement, commercialization, and competitive risks typical of biomarker-based medical products, where clinical uptake can be slower than expected and evidence requirements are high.

- **Regulatory access risk** [high] — Sales depend on maintaining and expanding CE mark and FDA-related approvals across markets.
- **Single-platform concentration** [high] — The company is centered on NGAL and kidney biomarker products, creating product concentration risk.
- **Clinical adoption risk** [medium] — Hospitals and laboratories may adopt new biomarker tests slowly due to workflow and evidence requirements.
- **Reimbursement and procurement risk** [medium] — Even medically useful diagnostics can face slow uptake if payment and purchasing pathways are uncertain.

- Dependence on regulatory clearances and registrations
- Commercial adoption risk for a specialized biomarker test
- Concentration on NGAL and kidney diagnostics
- Reimbursement and procurement hurdles in healthcare markets
- Competition from alternative AKI diagnostics and standard care

## Accounting

BioPorto uses IFRS reporting, and its results can be affected by judgment-heavy items such as share-based compensation, deferred tax assets, and gains or losses on asset disposals. The interim report also shows that divestments and non-recurring items can materially affect operating income, while warrant accounting affects equity and personnel expense recognition over time.

- **Deferred tax asset recoverability** — Can materially affect equity and tax expense presentation
- **Divestment gain recognition** — Can distort comparability of underlying operating performance
- **Share-based compensation** — Affects personnel cost and equity
- **Receivables impairment** — Affects net revenue realization and working capital

- Recognition of gain on divestment of business activities
- Deferred tax asset recoverability depends on future taxable profits
- Warrant accounting affects share-based compensation and equity
- Bad debt estimates affect trade receivables valuation
- Interim reporting can include non-recurring items and seasonality

---

*Last updated: 2026-10-24T15:02:11.415863+00:00*